Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.（CRL）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
crl · 股价预测 · 37 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 37 位华尔街分析师
Buy
37 位分析师
共识
评级分布
12 个月目标价
High
$220
Consensus
$213
+14.3% upside
Low
$192
Median: $217 · Last Close: $186.44
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$213.17
14.3% upside
High Target
$220
18.0%
Low Target
$192
3.0%
Current Price
$186.44
as of today
Based on analyst price targets, the CRL stock price prediction for the next 12 months ranges from $192 to $220. The consensus CRL price forecast of $213.17 implies 14.3% upside from the current price of $186.44.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $195.76 | ↑ 5.00% |
1-day model range: $194.5–$197.03. Peak: $197.03 (+5.00%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $193 | +3.4% |
| 2028 | $197 | +5.6% |
| 2029 | $199 | +6.9% |
| 2030 | $201 | +7.7% |
| 2031 | — | +8.2% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CRL · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-29 | CLSA | Upgrade ↑ | Hold→Outperform |
| 2026-05-08 | Barclays | Maintains | Overweight→Overweight |
| 2026-05-08 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-04-14 | Barclays | Maintains | Overweight→Overweight |
| 2026-04-13 | JP Morgan | Maintains | Neutral→Neutral |
| 2026-02-25 | UBS | Maintains | Neutral→Neutral |
| 2026-02-20 | Mizuho | Maintains | Neutral→Neutral |
| 2026-02-20 | TD Cowen | Maintains | Buy→Buy |
| 2026-02-19 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-02-19 | Barclays | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Charles River Laboratories International, Inc. (CRL) stock. Of the recent 265 rating actions, 37 were upgrades and 28 were downgrades. 37 analysts currently cover CRL.
分析师推荐趋势
CRL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 3 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$3.8B
↓ 5.9% YoY
Revenue Next Year
$3.9B
↑ 1.8% YoY
EPS This Year
$11.09
EPS Next Year
$12.32
↑ 11.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRL EPS of $11.09 for the current fiscal year, based on estimates from 10 analysts. The CRL revenue forecast is $3.8B for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
CRL 股价预测由两类独立数据源支撑：来自 37 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CRL 的共识目标价为 $213.17（+14.3% 上行空间），分析师共识为 Buy。
CRL 的短期预测（明日）为 $195.76（+5.00%）。 CRL 对 2027 年的股价预测均值为 $193。 CRL 对 2030 年的预测区间为 $187–$215。
Charles River Laboratories International, Inc. 在 NYSE 上市，代码 CRL。CRL 在 2027 年的整体展望偏积极，在覆盖分析师中约 70% 对应 Buy 共识。
常见问题
CRL 预测 · 8 个问题根据 37 位华尔街分析师，CRL 的 12 个月平均目标价为 $213.17，最高 $220.00、最低 $192.00。若有图表，中位目标价可在上方查看。相对当前价 $186.44，隐含约 +14.3% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.